Advanced Pancreatic Cancer: Expert Perspectives on Treatment and Emerging Therapies

Released On
June 24, 2020

Expires On
June 24, 2021

Media Type
Internet

Completion Time
60 minutes

Specialty
Hematology-Oncology

Topic(s)
Oncology

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Paradigm Medical Communications, LLC.

This activity is supported by educational grants from Celgene Corporation, Erytech, and Ipsen Biopharmaceuticals, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity has been designed to address the educational needs of oncology physicians and advanced practitioners practicing in community and academic settings. It will also be of benefit to oncology nurses, pathologists, interventional radiologists, residents, fellows, and other clinicians who treat patients with pancreatic cancer.

Program Overview

Given the very poor outcomes for patients with pancreatic cancer and owing to a lack of awareness among a large proportion of oncology clinicians of the efficacy of guideline-recommended, multiagent chemotherapy regimens, it is critical that oncology clinicians offer their patients the best choice of potentially life-prolonging treatment. Oncology clinicians would benefit from this educational activity through updates on a multidisciplinary approach to optimally managing patients with pancreatic cancer, with a focus on the efficacy and safety data of current guideline-recommended regimens as well as information on emerging therapies.

Learning Objectives

Upon proper completion of this activity, participants should be better able to:

  • Incorporate guideline-recommended diagnostic and pathologic tests for patients with metastatic pancreatic cancer
  • Apply the latest clinical trial data and current guidelines to optimally select treatment for patients with metastatic pancreatic cancer
  • Review the latest data for emerging treatments of metastatic pancreatic cancer, and the potential benefits for patients enrolled in trials of these therapies

Faculty

Steering Committee

Eileen M. O'Reilly, MD

Eileen M. O'Reilly, MD

Winthrop Rockefeller Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers
Associate Director, David M. Rubenstein Center for Pancreatic Cancer Research
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY

Zev A. Wainberg, MD

Zev A. Wainberg, MD

Associate Professor of Medicine and Surgery
Co-Director, GI Oncology Program
Director, Early Phase Development Program
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, CA

Contributing Faculty

Christopher H. Crane, MD

Vice Chairman and Attending
Memorial Sloan Kettering Cancer Center
New York, NY

Mark Schattner, MD, FASGE, AGAF

Chief, Gastroenterology, Nutrition, and Hepatology Service
Memorial Sloan Kettering Cancer Center
Professor of Clinical Medicine
Weil Cornell College of Medicine
New York, NY

Alice C Wei, MD, MSc

Associate Attending Surgeon
Hepatopancreatobiliary Service
Department of Surgery
Memorial Sloan Kettering Cancer Center
New York, NY

Accreditation Statement

Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Paradigm Medical Communications, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosures of Conflicts of Interest

Eileen M. O'Reilly, MD

  • Grant/Research Support (Self): ActaBiologica; Agios, Inc; Array BioPharma; AstraZeneca, Bayer HealthCare; BeiGene; Bristol-Myers Squibb Company; Casi Pharmaceuticals Inc; Celgene Corporation; Exelixis, Inc; Genentech, Inc; Mabvax Therapeutics, Inc; Novartis Pharmaceuticals Corporation; Polaris Pharmaceuticals; Puma Biotechnology, Inc; QED Therapeutics; Roche
  • Grant/Research Support (Spouse): ActaBiologica; Agios, Inc; Array BioPharma; AstraZeneca, Bayer HealthCare; BeiGene; Bristol-Myers Squibb Company; Casi Pharmaceuticals Inc; Celgene Corporation; Exelixis, Inc; Genentech, Inc; Mabvax Therapeutics, Inc; Novartis Pharmaceuticals Corporation; Polaris Pharmaceuticals; Puma Biotechnology, Inc; QED Therapeutics; Roche
  • Retained Consultant (Self): AstraZeneca, Celgene Corporation; CytomX Therapeutics, Inc; Ipsen Biopharmaceuticals, Inc; Merck & Co., Inc; Pfizer Inc; Polaris Pharmaceuticals; Silenseed LTD; Sobi; Targovax;
  • Retained Consultant (Spouse): Agios, Inc; AstraZeneca, Bayer HealthCare; BeiGene; Bristol-Myers Squibb Company; Celgene Corporation; Debiopharm Group; Eisai; Eli Lilly and Company; Exelixis, Inc; Flatiron; Genoscience Pharma; Incyte; Ipsen Biopharmaceuticals, Inc; LAM Inc; Merck & Co., Inc; MINAPHARM Pharmaceuticals; QED Therapeutics; Redhill; sanofi-aventis U.S. LLC; SillaJen, Inc; Vicus Therapeutics, LLC; Yiviva

Zev Wainberg, MD

  • Grant/Research Support: Bristol-Myers Squibb Company; Eli Lilly and Company; Ipsen Biopharmaceuticals, Inc; Merck & Co., Inc; Novartis Pharmaceuticals Corporation
  • Retained Consultant: Bayer HealthCare; Eli Lilly and Company; Ipsen Biopharmaceuticals, Inc; Merck & Co, Inc

Contributing Faculty

Christopher H. Crane, MD

  • No financial relationships to disclose.

Mark Schattner, MD, FASGE, AGAF

  • Retained Consultant: Boston Scientific

Alice C. Wei, MD, MSc

  • Other (Travel Fees): Bayer Pharmaceuticals; Intuitive Pharma

Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.

Independent peer and resident/fellow reviewers have no financial relationships to disclose.

Resolution of Conflict of Interest

Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.

Instructions for Participation and Credit

How to Receive Your CME Credit
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  • Review the activity in its entirety
  • Complete and return the activity postsurvey, evaluation, and request for credit forms
A certificate of participation will be issued 1 to 2 weeks following the completion of the activity.
For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.

Hardware and Software Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.

Disclaimer

This CME activity represents the views and opinions of the individual faculty member and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

If included, signed statements of informed consent granting permission for use have been obtained for all photographs and videos in which an individual can be identified.

As an ACCME-accredited provider, Paradigm Medical Communications, LLC activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.

© 2020 Paradigm Medical Communications, LLC, except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.